1.Foa, EB, Franklin, ME, Moser, J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry. 2002;10:987–997.
2.Otto, MW, Smits, JAJ, Reese, HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clinical Psychology: Science and Practice. 2005;12:72–86.
3.Davidson, JR, Foa, EB, Huppert, JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004;61:1005–1013.
4.Foa, EB, Liebowitz, MR, Kozak, MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162:151–161.
5.van Balkom, AJ, de Haan, E, van Oppen, P, et al. Cognitive and behavioral therapies alone and in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis. 1998;186:492–499.
6.Franklin, ME, Abramowitz, JS, Bux, DA, Zoellner, LA, Feeny, NC. Cognitive-behavioral therapy with and without medication in the treatment of obsessive-compulsive disorder. Professional Psychology: Research and Practice. 2002;33:162–168.
7.Kampman, M, Keijsers, GP, Hoogduin, CA, Hendriks, GJ. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry. 2002;63:772–777.
8.Otto, MW, Pollack, MH, Penava, SJ, Zucker, BG. Cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. Behav Res Ther. 1999;37:763–770.
9.Heldt, E, Gus Manfro, G, Kipper, L, Blaya, C, Isolan, L, Otto, MW. One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behavior therapy: outcome and predictors of remission. Behav Res Ther. 2006;44:657–665.
10.Barlow, DH, Gorman, JM, Shear, MK, Woods, SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA. 2000;283:2529–2536.
11.de Beurs, E, van Balkom, AJ, Lange, A, Koele, P, van Dyke, R. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry. 1995;152:683–691.
12.Furukawa, TA, Watanabe, N, Chruchill, R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia. Br J Psychiatry. 2006;188:305–312.
13.Marks, IM, Swinson, RP, Basaglu, M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br J Psychiatry. 1993;162:776–787.
14.Powers, MB, Smits, JAJ, Leyro, TM, Otto, M. Translational research perspectives on maximizing the effectiveness of exposure therapy. In: Richard, DCS, Lauterbach, D, eds. Comprehensive Handbook of the Exposure Therapies. Orlando, FL: Academic Press; 2006:109–126.
15.Bouton, ME. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry. 2002;52:976–986.
16.Bouton, ME. Context and behavioral processes in extinction. Learn Mem. 2004;11:485–494.
17.Bouton, ME, Kenney, FA, Rosengard, C. State dependent fear extinction with two benzodiazepine tranquilizers. Behav Neurosci. 1990;104:44–55.
18.Rescorla, RA. Experimental extinction. In: Mowrer, RR, Klein, SB, eds. Handbook of Contemporary Learning Theories. Mahwah, NJ: Erlbaum; 2001:119–154.
19.Mystkowski, JL, Mineka, S, Vernon, LL, Zinbarg, RE. Changes in caffeine states enhance return of fear in spider phobia. J Consult Clin Psychol. 2003;71:243–250.
20.Foa, EB, Kozak, MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull. 1986;99:20–35.
21.Powers, MB, Smits, JA, Telch, MJ. Disentangling the effects of safety-behavior utilization and safety-behavior availability during exposure-based treatment: a placebo-controlled trial. J Consult Clin Psychol. 2004;72:448–454.
22.Kamphuis, JH, Telch, MJ. Effect of distraction and guided threat reappraisal on fear reduction during exposure-based treatments for specific fears. Behav Res Ther. 2000;38:1163–1181.
23.Rodriguez, BI, Craske, MG. The effects of distraction during exposure to phobic stimuli. Behav Res Ther. 1993;31:549–558.
24.Otto, MW, Pollack, MH, Sabatino, SA. Maintenance of remission following cognitive-behavior therapy for panic disorder: possible deleterious effects of concurrent medication treatment. Behav Ther. 1996;27:473–482.
25.Davis, M, Falls, WA, Gewirtz, J. Neural systems involved in fear inhibition: extinction and conditioned inhibition. In: Myslobodsky, M, Weiner, I, eds. Contemporary Issues in Modeling Psychopathology. Boston, Mass: Kluwer Academic Publishers; 2000:113–142.
26.Davis, M, Myers, KM. The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry. 2002;52:998–1007.
27.Davis, M, Myers, KM, Ressler, KJ, Rothbaum, BO. Facilitation of extinction of conditioned fear by D-cycloserine: implications for psychotherapy. Current Directions in Psychological Science. 2005;14:214–219.
28.Richardson, R, Ledgerwood, L, Cranney, J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem. 2004;11:510–516.
29.Ledgerwood, L, Richardson, R, Cranney, J. D-cycloserine facilitates extinction of learned fear: effects of reacquisition and generalized extinction. Biol Psychiatry. 2005;57:841–847.
30.Ressler, KJ, Rothbaum, BO, Tannenbaum, L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobics to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:1136–1144.
31.Nair, K, Epstein, I, Baron, H, Mulinos, M. Absorption, distribution, and excretion of cycloserine in man. Antibiot Ann. 1956:136–140.
32.D'Souza, DC, Gil, R, Cassello, K, et al. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry. 2000;47:450–462.
33.Hofmann, SG, Meuret, AE, Smits, JAJ, et al. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63:298–304.
34.Katzelnick, DJ, Kobak, KA, DeLeire, T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158:1999–2007.
35.Schneier, FR, Heckelman, LR, Garfinkel, R, et al. Functional impairment in social phobia. J Clin Psychiatry. 1994;55:322–331.
36.Heresco-Levy, U, Kremer, I, Javitt, DC, et al. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol. 2002;5:301–307.
37.van Berckel, BN, Lipsch, C, Timp, S, et al. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology. 1997;16:317–324.
38.van Berckel, BN, Lipsch, C, Gispen-de Wied, C, et al. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl). 1998;138:190–197.
39.Physicians Desk Reference. 60th ed. Montvale, NJ: Thomson PDR: 2006.
40.Quartermain, D, Mower, J, Rafferty, MF, Herting, RL, Lanthorn, TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;157:7–12.
41.Parnas, AS, Weber, M, Richardson, R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem. 2005;83:224–231.
42.Boje, KM, Wong, G, Skolnick, P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res. 1993;603:207–214.
43.Randolph, C, Roberts, JW, Tierney, MC, Bravi, D, Mouradian, MM,Chase, TN. D-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 1994;8:198–205.
44.Tuominen, HJ, Tiihonen, J, Wahlbeck, K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Res. 2005;72:225–234.
45.Evins, AE, Amico, E, Posever, TA, Toker, R, Goff, DC. D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Res. 2002;56:19–23.
46.Goff, DC, Tsai, G, Manoach, DS, Coyle, JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms of schizophrenia. Am J Psychiatry. 1995;152:1213–1215.
47.Goff, DC, Coyle, JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158:1367–1377.
48.Goff, DC, Tsai, G, Levitt, J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1996;56:21–27.
49.Duncan, EJ, Szilagyi, S, Schwartz, MP, et al. Effects of D-cycloserine on negative symptoms of schizophrenia. Schizophrenia Res. 2004;71:239–248.
50.Goff, DC, Herz, L, Posever, T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychpharmacology. 2005;179:144–150.
51.Goff, DC. Tsai, G, Manoach, DS, et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996;153:1628–1630
52.van Berckel, BN, Hijman, R, van der Linden, JA, Westenberg, HG, van Ree, JM, Kahn, RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 1996;40:1298–1300.
53.Heresco-Levy, U, Javitt, DC, Ermilov, M, Silipo, G, Shimoni, J. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 1998;1:131–135.
54.Goff, DC, Henderson, DC, Evins, E, Amico, E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;45:512–514.
55.Heresco-Levy, U, Ermilov, M, Shimoni, J, Shapira, B, Silipo, G, Javitt, DC. Placebo-controlled trial of D-cylcoserine added to cconventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002;159:480–482.
56.Rosse, RB, Fay-McCarthy, M, Kendrick, K, Davis, RE, Deutsch, SI. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol. 1996;19:444–450.
57.van Berckel, BN, Evenblij, CN, van Loon, AM, et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999;21:203–210.
58.Yurgelun-Todd, DA, Coyle, JTGruber, SA, et al. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005;138:23–31.
59.Tsai, GE, Falk, WE, Gunther, J, Coyle, JT. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999;156:467–469.
60.Fakouhi, TD, Jhee, SS, Sramek, JJ, et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol. 1995;8:226–230.
61.Tsai, GE, Falk, WE, Gunther, J. A preliminary study of d-cycloserine treatment in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1998;10:224–226.
62.Laake, JR, Oeksengaard, AR. D-cycloserine for Alzheimer's disease. (Cochrane Review). The Cochrane Database of Systematic Reviews. 2002, Issue 2. Art. No.: CD003153. DOI:10.1002/14651858.CD003153.
63.Ledgerwood, L, Richardson, R, Cranney, J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci. 2003;117:341–349.
64.Barlow, DH, ed. Clinical Handbook of Psychological Disorders. 3rd ed. New York: Guilford Press; 2001.
65.Hofmann, SG, Tompson, MC, eds. Treating Chronic and Severe Mental Disorders: A Handbook of Empirically Supported Interventions. New York, NY: Guilford Press; 2002.
66.Land, C, Riccio, D. D-cycloserine: effects on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiol Learn Mem. 1999;72:158–168.
67.Pussinen, R, Sirvio, J. Effects of D-cycloserine, a positive modulator of N-methyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze. J Psychopharmacol. 1999;13:171–179.
68.Lelong, V, Dauphin, F, Boulouard, M. RS 67333 and D-cycloserine accelerate learning acquisition in the rat. Neuropharmacology. 2001;41:517–522.
69.Pitkanen, M, Sirvio, J, MacDonald, E, Niemi, S, Ekonsalo, T, Riekkinen, P Sr. European Neuropsychopharmacology. 1995;5:457–63.